A message from Juan Martinez, Head of Curaleaf International
As 2024 draws to a close, it’s clear this year has been pivotal for both Curaleaf International and the cannabis industry at large. From regulatory advancements to operational milestones, the progress we’ve seen reflects an industry on the cusp of even greater transformation.
Germany leads with bold reform
This year’s most significant moment was Germany’s decision to remove cannabis from its narcotics list. More than just a legislative change, this was a landmark the global cannabis industry, setting a clear precedent for how regulation can foster innovation while safeguarding public health. Since April 1st, the patient population in Germany has almost tripled.
However, recent political developments, including the possibility of snap elections in Germany, add a layer of uncertainty to the future of cannabis regulation. The Christian Democratic Union of Germany (CDU) has voiced intentions to reverse the traffic light coalition’s cannabis law as one of its first measures if it takes office. That said, the CDU may face difficulty finding a coalition partner willing to support “recriminalisation.” The industry must remain vigilant and proactive to sustain the progress made.
UK operators’ steady progress in patient care
UK operators continue to make meaningful strides in expanding access to medical cannabis. However, significant hurdles remain. The government is imposing stricter requirements, such as labelling changes, and little has been done to provide insurance coverage for clinic consultations and products.
Despite these challenges, the increasing number of private clinics, alongside more affordable pricing and greater variety in product formulations, is giving patients real options. For many, this represents the beginning of long-overdue change in how cannabis-based treatments are understood and accessed.
We still have a long way to go. Through our report, The Hidden Dangers of Illicit Cannabis, we uncovered the potential harm caused by unregulated cannabis, including contamination from mould, yeasts, bacteria, and heavy metals. Regulators must take note and act.
Expanding our global reach
On the operational front, Curaleaf International has made key investments to support our growth in Europe and beyond. This was highlighted in the recent BBC News feature, which had exclusive access to our cultivation and processing facility in Portugal and pharmacy operations in Sunderland. Our acquisition of Northern Green Canada has not only strengthened our supply chain but also positioned us strategically for expansion into high-growth markets like Australia and New Zealand. In Poland, the new Curaleaf team is ready for opportunities in this growing market. With scalability and stability as priorities, we can meet the needs of patients and healthcare providers as demand continues to rise.
Addressing laggards and gaps
While progress has been made, some countries remain conspicuously behind. Portugal, despite exporting over 25 tons of cannabis annually as the world’s second-largest exporter, faces an almost non-existent domestic market. Only a few hundred packages are distributed monthly, and prescriptions are decreasing—highlighting the disparity between its global influence and local accessibility.
Poland has taken a regressive step by banning telemedicine clinics for medical cannabis, limiting patient access at a time when convenience and healthcare should go hand in hand. Meanwhile, major players like Italy, France, and Spain are lacking in implementing effective cannabis policies. Italy’s cautious approach and restrictive measures have stifled patient access. France’s pilot program remains small in scope, delaying meaningful reform, and Spain has yet to provide a clear regulatory framework despite its progressive cultural stance. These disparities underscore the need for unified action to bring cannabis policy into the 21st century across Europe.
A collaborative industry
2024 has also underscored the maturing nature of the cannabis industry. Conversations have moved from speculation to substance, with stakeholders—from policymakers to healthcare providers—collaborating on evidence-based solutions. This evolution is critical for breaking down misconceptions and building trust in cannabis as part of mainstream healthcare systems. Research and education must continue to be the foundation this industry is built upon.
Driving innovation, shaping the future
As we look ahead to 2025, our focus is clear: expand access for patients, advocate for smarter policies, and continue leading with research and innovation. The opportunities ahead are immense, from shaping evolving regulatory landscapes to driving progress in untapped markets. Evidence-based medicine will be the cornerstone of the industry’s future, and Curaleaf International is committed to leading the way in this area.
To everyone we’ve partnered with, collaborated with, or connected with in 2024 — thank you. Together, we are shaping the future of cannabis and creating a global market built on trust, innovation, and care. Here’s to what lies ahead.
